- $713.94m
- $692.56m
- $70.01m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 50.24 | ||
PEG Ratio (f) | 1.92 | ||
EPS Growth (f) | 35.45% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.77 | ||
Price to Tang. Book | 19.34 | ||
Price to Free Cashflow | 86.86 | ||
Price to Sales | 9.09 | ||
EV to EBITDA | 48.83 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 3.24% | ||
Return on Equity | 4.01% | ||
Operating Margin | 7.86% |
Financial Summary
Year End 31st Aug | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 41.59 | 46.47 | 53.91 | 59.58 | 70.01 | 90.38 | 101.2 | 15.56% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +7.78 | -3.92 | +24.5 | -15.92 | -17.41 | +34.64 | +35.78 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
Directors
- Walter Woltosz CHM (76)
- Shawn O'Connor CEO (62)
- William Frederick CFO (57)
- John DiBella CEX (42)
- Jill Fiedler-kelly CEX (52)
- Brett Howell CEX (38)
- Sharlene Evans IND (57)
- Lisa LaVange IND (68)
- John Paglia IND (54)
- Daniel Weiner IND (71)
- Last Annual
- August 31st, 2024
- Last Interim
- February 28th, 2025
- Incorporated
- July 17th, 1996
- Public Since
- June 18th, 1997
- No. of Shareholders
- 37
- No. of Employees
- 243
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market
- Shares in Issue
- 20,111,045

- Address
- 800 Park Offices Drive, Suite 401, RESEARCH TRIANGLE PARK, 27709
- Web
- https://www.simulations-plus.com/
- Phone
- +1 6617237723
- Contact
- Lisa Fortuna
- Auditors
- Rose, Snyder & Jacobs
Upcoming Events for SLP
Q4 2025 Simulations Plus Inc Earnings Release
Similar to SLP
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 23:16 UTC, shares in Simulations Plus are trading at $35.50. This share price information is delayed by 15 minutes.
Shares in Simulations Plus last closed at $35.50 and the price had moved by -22.23% over the past 365 days. In terms of relative price strength the Simulations Plus share price has underperformed the S&P500 Index by -28.22% over the past year.
The overall consensus recommendation for Simulations Plus is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Simulations Plus dividend yield is 0.51% based on the trailing twelve month period.
Last year, Simulations Plus paid a total dividend of $0.18, and it currently has a trailing dividend yield of 0.51%. We do not have any data on when Simulations Plus is to next pay dividends.
We do not have data on when Simulations Plus is to next pay dividends. The historic dividend yield on Simulations Plus shares is currently 0.51%.
To buy shares in Simulations Plus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $35.50, shares in Simulations Plus had a market capitalisation of $713.94m.
Here are the trading details for Simulations Plus:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SLP
Based on an overall assessment of its quality, value and momentum Simulations Plus is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Simulations Plus is $46.60. That is 31.27% above the last closing price of $35.50.
Analysts covering Simulations Plus currently have a consensus Earnings Per Share (EPS) forecast of $0.57 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Simulations Plus. Over the past six months, its share price has outperformed the S&P500 Index by +21.96%.
As of the last closing price of $35.50, shares in Simulations Plus were trading +10.6% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Simulations Plus PE ratio based on its reported earnings over the past 12 months is 50.24. The shares last closed at $35.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Simulations Plus' management team is headed by:
- Walter Woltosz - CHM
- Shawn O'Connor - CEO
- William Frederick - CFO
- John DiBella - CEX
- Jill Fiedler-kelly - CEX
- Brett Howell - CEX
- Sharlene Evans - IND
- Lisa LaVange - IND
- John Paglia - IND
- Daniel Weiner - IND